Literature DB >> 12874012

A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.

Zhihai Qin1, Johannes Schwartzkopff, Felicia Pradera, Thomas Kammertoens, Barbara Seliger, Hanspeter Pircher, Thomas Blankenstein.   

Abstract

It is thought that tumor rejection by CD8(+) T-cell effectors is primarily mediated by direct killing. We show that rejection of different tumors (fibrosarcoma, ras-transformed fibroblasts, colon carcinoma, and plasmacytoma) by CD8(+) T cells is always preceded by inhibition of tumor-induced angiogenesis. Angiostasis and tumor rejection were observed in perforin but not in IFN-gamma-deficient mice. Furthermore, adoptive transfer of tumor-specific CD8(+) T cells from IFN-gamma-competent mice inhibited angiogenesis of lung metastases in comparison to those from IFN-gamma gene-deficient mice. Taken together with our previous findings, we conclude that IFN-gamma-dependent antiangiogenesis is a general mechanism involved in tumor rejection by CD4(+) and CD8(+) T-cell effectors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874012

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  79 in total

1.  IFN-γ promotes graft-versus-leukemia effects without directly interacting with leukemia cells in mice after allogeneic hematopoietic cell transplantation.

Authors:  Yanping Yang; Hui Wang; Hui Yu; Beow Yong Yeap; Tingting Liang; Guanjun Wang; Tao Cheng; Yong-Guang Yang
Journal:  Blood       Date:  2011-08-11       Impact factor: 22.113

Review 2.  Immune profiling and cancer post transplantation.

Authors:  Christopher Martin Hope; Patrick Toby H Coates; Robert Peter Carroll
Journal:  World J Nephrol       Date:  2015-02-06

3.  The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Authors:  Marilyn Giordano; Romain Roncagalli; Pierre Bourdely; Lionel Chasson; Michel Buferne; Sho Yamasaki; Rudi Beyaert; Geert van Loo; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Grégory Verdeil
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

4.  Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Authors:  Thomas Kammertoens; Christian Friese; Ainhoa Arina; Christian Idel; Dana Briesemeister; Michael Rothe; Andranik Ivanov; Anna Szymborska; Giannino Patone; Severine Kunz; Daniel Sommermeyer; Boris Engels; Matthias Leisegang; Ana Textor; Hans Joerg Fehling; Marcus Fruttiger; Michael Lohoff; Andreas Herrmann; Hua Yu; Ralph Weichselbaum; Wolfgang Uckert; Norbert Hübner; Holger Gerhardt; Dieter Beule; Hans Schreiber; Thomas Blankenstein
Journal:  Nature       Date:  2017-04-26       Impact factor: 49.962

5.  Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.

Authors:  Katherine A Murphy; Britnie R James; Yue Guan; Donald S Torry; Andrew Wilber; Thomas S Griffith
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis.

Authors:  Elisa Ferretti; Emma Di Carlo; Emanuela Ognio; Giulio Fraternali-Orcioni; Anna Corcione; Beatrice Belmonte; Jean Louis Ravetti; Claudio Tripodo; Domenico Ribatti; Vito Pistoia
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

7.  Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.

Authors:  Jie Zhang; Ying Wang; Yang Wu; Zhen-Yu Ding; Xin-Mei Luo; Wu-Ning Zhong; Jie Liu; Xiang-Yu Xia; Guo-Hua Deng; Yao-Tiao Deng; Yu-Quan Wei; Yu Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-14       Impact factor: 4.553

Review 8.  Intravital imaging of CD8+ T cell function in cancer.

Authors:  Thorsten R Mempel; Christian A Bauer
Journal:  Clin Exp Metastasis       Date:  2008-07-30       Impact factor: 5.150

9.  Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Authors:  Benedetto Farsaci; Renee N Donahue; Michael A Coplin; Italia Grenga; Lauren M Lepone; Alfredo A Molinolo; James W Hodge
Journal:  Cancer Immunol Res       Date:  2014-08-04       Impact factor: 11.151

10.  The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells.

Authors:  Bent Rubin; Joëlle Riond; Laetitia Courtiade; Nicolas Roullet; Jean-Edouard Gairin
Journal:  Cancer Immun       Date:  2008-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.